Novo Nordisk A/S (NVO)vsPACCAR Inc (PCAR)
NVO
Novo Nordisk A/S
$36.33
-1.52%
HEALTHCARE · Cap: $165.02B
PCAR
PACCAR Inc
$116.34
+0.47%
INDUSTRIALS · Cap: $60.90B
Smart Verdict
WallStSmart Research — data-driven comparison
Novo Nordisk A/S generates 987% more annual revenue ($309.06B vs $28.44B). NVO leads profitability with a 33.1% profit margin vs 8.3%. PCAR appears more attractively valued with a PEG of 1.11. NVO earns a higher WallStSmart Score of 55/100 (C).
NVO
Buy55
out of 100
Grade: C
PCAR
Hold46
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-59.4%
Fair Value
$24.21
Current Price
$36.33
$12.12 premium
Margin of Safety
-321.2%
Fair Value
$30.74
Current Price
$116.34
$85.60 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Every $100 of equity generates 61 in profit
Keeps 33 of every $100 in revenue as profit
Strong operational efficiency at 44.5%
Large-cap with strong market position
Large-cap with strong market position
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Revenue declined 7.6%
Earnings declined 4.7%
Moderate valuation
Weak financial health signals
Revenue declined 13.7%
Earnings declined 35.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : NVO
The strongest argument for NVO centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 33.1% and operating margin at 44.5%.
Bull Case : PCAR
The strongest argument for PCAR centers on Market Cap. PEG of 1.11 suggests the stock is reasonably priced for its growth.
Bear Case : NVO
The primary concerns for NVO are Piotroski F-Score, PEG Ratio, Revenue Growth.
Bear Case : PCAR
The primary concerns for PCAR are P/E Ratio, Piotroski F-Score, Revenue Growth.
Key Dynamics to Monitor
NVO profiles as a declining stock while PCAR is a value play — different risk/reward profiles.
PCAR carries more volatility with a beta of 1.05 — expect wider price swings.
NVO is growing revenue faster at -7.6% — sustainability is the question.
PCAR generates stronger free cash flow (778M), providing more financial flexibility.
Bottom Line
NVO scores higher overall (55/100 vs 46/100), backed by strong 33.1% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novo Nordisk A/S
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.
PACCAR Inc
INDUSTRIALS · FARM & HEAVY CONSTRUCTION MACHINERY · USA
PACCAR Inc is an American Fortune 500 company and counts among the largest manufacturers of medium- and heavy-duty trucks in the world. PACCAR is engaged in the design, manufacture and customer support of light-, medium- and heavy-duty trucks under the Kenworth, Peterbilt, Leyland Trucks, and DAF nameplates. PACCAR also designs and manufactures powertrains, provides financial services and information technology, and distributes truck parts related to its principal business.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?